The vaccine has been phased out in several countries in recent days following reports of blood clots.

Coronavirus – the second year

It has been more than a year since the Chinese authorities informed the WHO of the emergence of a new, rapidly spreading virus. Since then, there has hardly been a person in the world who has not heard the term Covid-19, and more and more people are mourning a family member or friend with whom the new disease ended as stocks collapsed in weeks and our entire lives. they were rewritten. by the epidemic. By now, the vaccines have been completed, which in turn raises not only hope, but again many questions, while not only stopping the virus, but also threatening another mutation. You will find the details of this fight in our series of articles.

AstraZeneca, a pharmaceutical company, said Sunday that no scientific evidence suggests that the vaccine developed by the company against the new type of coronavirus would increase the risk of blood clots.

As a prelude to a statement issued by the British-Swedish pharmaceutical group in London on Sunday night, several countries – Norway, Bulgaria, Denmark, Iceland and Italy and Ireland on Sunday – have decided to suspend the use of a vaccine jointly developed by AstraZeneca. . and Oxford University following a reported blood clot case in some patients vaccinated with this vaccine.

However, AstraZeneca emphasized in a statement Sunday that a careful safety study of the more than 17 million doses of vaccines administered so far in the European Union and the United Kingdom did not provide any evidence that the vaccine was used in any group. of age, in any country, in either sex, or increase the risk of pulmonary embolism, deep vein thrombosis (DVT) or abnormal platelet counts in any vaccine shipment.

The company said there were 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism in the European Union and the United Kingdom, based on data received as of March 8, among those vaccinated with AstraZeneca / Oxford. This is far less than the number of cases that can occur in a population of this size for natural reasons and is similar to the number of cases reported after the use of other licensed vaccines, according to AstraZeneca’s Sunday night newsletter.

Ann Taylor, AstraZenca’s chief medical officer, also said in a statement to the announcement that 17 million patients vaccinated with the company’s vaccine have reported fewer cases of blood clots than would be the case in the general population, with hundreds of patients. Similar. would be expected.

According to AstraZeneca, there were no confirmed quality issues with any of the vaccine shipments.

The company is closely monitoring reports of blood clots, but the available data does not prove these were caused by the vaccine, they wrote in the Sunday night newsletter.

The UK Medicines Agency (MHRA) also said in its daily report that there was no confirmed causal link between the AstraZeneca vaccine and the cases of blood clots found.

In a statement Thursday, the MHRA emphasized that 11 million doses of AstraZeneca had so far been administered in the UK and that there were no more reports of blood clots than there would have been for natural reasons in the vaccinated population during the same period. period.



The number of independent editorial boards of power is steadily declining, and those that still exist are trying to stay afloat in a growing headwind. At HVG we persevere, we do not give in to pressure and we bring national and international news every day.

That is why we ask you, our readers, to support us, support us, join our membership and renew it!

And we promise to continue to do our best for you in all circumstances!

AstraZeneca has acknowledged that it supplies fewer vaccines to the union



hvg.hu
Economy

According to the new calendar, the twenty will receive 30.1 million doses of the company’s vaccine at the end of March.

They are also temporarily stopped using the AstraZeneca vaccine in Ireland.



hvg.hu
Technology

This was decided due to the widespread cases of blood clots in the news.